ASCO GI 2021 | KEYNOTE-224: pembrolizumab monotherapy for previously untreated HCC

Jean-Luc Van Laethem, MD, PhD, Erasme Hospital University, Brussels, Belgium, discusses the results of the KEYNOTE-224 study (NCT02702414), a Phase II trial evaluating pembrolizumab monotherapy for previously untreated hepatocellular carcinoma (HCC). Checkpoint blockade in these patients demonstrated durable anti-tumor activity, promising overall survival, and no new associated safety signals. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).